ES2649156T3 - Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim - Google Patents

Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim Download PDF

Info

Publication number
ES2649156T3
ES2649156T3 ES14702167T ES14702167T ES2649156T3 ES 2649156 T3 ES2649156 T3 ES 2649156T3 ES 14702167 T ES14702167 T ES 14702167T ES 14702167 T ES14702167 T ES 14702167T ES 2649156 T3 ES2649156 T3 ES 2649156T3
Authority
ES
Spain
Prior art keywords
alkyl
nrc3rd3
membered
independently selected
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14702167T
Other languages
English (en)
Inventor
Yun-Long Li
David M. Burns
Hao Feng
Chu-Biao Xue
Anlai Wang
Jun Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Application granted granted Critical
Publication of ES2649156T3 publication Critical patent/ES2649156T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo, en donde: Cy es C3-7 cicloalquilo no sustituido o sustituido o heterocicloalquilo de 4-10 miembros sustituido o no sustituido, en donde los átomos del anillo del heterocicloalquilo consisten en átomos de carbono y 1, 2 o 3 heteroátomos seleccionados de O, N o S, en el que el C3-7 cicloalquilo sustituido o heterocicloalquilo sustituido de 4-10 miembros de formación de Cy está sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados cada uno independientemente de halógeno, RCy1, C1-6 haloalquilo, CN, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRe1)NRc1Rd1, NRc1C(>=NRe1)NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 y S(O)2NRc1Rd1 , en el que cada RCy1 se selecciona independientemente de C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C6-10 arilo, heteroarilo de 5-10 miembros, C3-7 cicloalquilo y heterocicloalquilo de 4-7 miembros, cada uno de los cuales es independientemente no sustituido o sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de halógeno, RCy2, C1-6 haloalquilo, CN, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(>=NRe1)NRc1Rd1, NRc1C(>=NRe1)NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 y S(O)2NRc1Rd1, y en el que cada RCy2 es independientemente C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C6-10 arilo, heteroarilo de 5- 10 miembros, C3-7 cicloalquilo y heterocicloalquilo de 4-7 miembros, cada uno de que es independientemente no sustituido o sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de halógeno, CN, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Ra1, NRc1Ra1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1 y S(O)2NRc1Rd1; A 1 es N o CR1; R1 es H, halógeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C1-6 haloalquilo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(>=NRe2)NRc2Rd2, NRc2C(>=NRe2)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 o S(O)2NRc2Rd2; y R2 es H, halógeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C1-6 haloalquilo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(>=NRe2)NRc2Rd2, NRc2C(>=NRe2)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 o S(O)2NRc2Rd2; o A1 y R2 en combinación, junto con el átomo de carbono al que R2 está unido, forman un anillo carbocíclico insaturado o parcialmente saturado de 5, 6 o 7 miembros o anillo heterocíclico que contiene 3 a 7 átomos de carbono en el anillo y 0, 1 o 2 heteroátomos en el anillo, cada uno seleccionado independientemente de N, o y S, donde el anillo formado por la combinación de A1 y R2 es no sustituido o sustituido por 1, 2 o 3 sustituyentes seleccionados independientemente de halógeno, C1-6 alquilo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Ra2, NRc2Rd2, NRcC(O)Rb2, NRc2C(O)NRc2Ra2, NRc2C(O)ORa2 y oxo; R3 es H, halógeno o NH2; R4 es H o halógeno; A5 es N o CR5; A6 es N o CR6; A7 es N o CR7; A8 es N o CR8; a condición de que 0, 1 o 2 de A5, A6, A7 y A8 son N; R5 es H o halógeno; R6 es H o halógeno; R7 es H, halógeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C1-6 haloalquilo, Cy7, -L7-Cy7, CN, ORa3, SRa3, C(O)Rb3 , C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C (O)NRc3Rd3, NRc3C(O)ORa3, C(>=NRe3)NRc3Rd3, NRc3C(>=NRe3)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3 o S(O)2NRc3Rd3, en el que dicho C1-6 alquilo, C2-6 alquenilo o C2-6 alquinilo R formandO7 son cada uno independientemente no sustituido o sub- stituted con 1, 2 o 3 sustituyentes seleccionados independientemente de halógeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C1-6 haloalquilo, CN, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(>=NRe3)NRc3Rd3, NRc3C(>=NRe3)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3 y S(O)2NRc3Rd3 ; Cy7 está no sustituido o sustituido C6-10 arilo, no sustituido o sustituido heteroarilo de 5-10 miembros, no sustituido o sustituido C3-6 cicloalquilo o no sustituido o sustituido de 4-7 miembros, heterocicloalquilo, en el que el sustituido C6-10 arilo, heteroarilo de 5-10 miembros, C3-6 cicloalquilo o heterocicloalquilo de 4-7 formando Cy7 está sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados cada uno independientemente de halógeno, RCy7, C2-6 alquenilo, C2-6 alquinilo, C1-6 haloalquilo, CN, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(>=NRe3)NRc3Rd3, NRc3C(>=NRe3)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3 y S(O)2NRc3Rd3 , en el que cada RCy7 es C1-6 alquilo, cada uno de los cuales es independientemente no sustituido o sustituido por 1, 2 o 3 subconstituyentes seleccionados independientemente de halógeno, CN, ORa3, SRa3, C(O)Rb3, C (O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(>=NRe3)NRc3Rd3, NRc3C(>=NRe3)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3 NRc3S(O)2Rb3 y S(O)2NRc3Rd3 ; L7 está no sustituido C1-6 alquileno o C1-6 alquileno sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente entre F, Cl, CN, OH, O (C1-6 alquilo), NH2, NH(C1-6 alquilo) y N(C1-6 alquilo)2; R8 es H, halógeno, CN o C1-6 alquilo; Ra1, Rb1, Rc1y Rd1 se seleccionan cada uno independientemente de H, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C6-10 arilo, C3-7 cicloalquilo, heteroarilo de 5-10 miembros, heterocicloalquilo de 4-10 miembros, C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo, en el que dicho C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo formando Ra1, Rb1, Rc1y Rd1 están cada uno opcionalmente sustituidos con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente de C1-6 alquilo, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(>=NRe4)NRc4Rd4, NRc4C(>=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4 y S(O)2NRc4Rd4 ; o Rc1y Rd1 unidos al mismo átomo de N, junto con el átomo de N al que están ambos unidos, forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros o grupo heteroarilo de 5 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de C1-6 alquilo, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(>=NRe4)NRc4Rd4, NRc4C(>=NRe4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4 y S(O)2NRc4Rd4 ; Ra2, Rb2, Rc2 y Rd2 se seleccionan cada uno independientemente de H, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C6-10 arilo, C3-7 cicloalquilo, heteroarilo de 5-10 miembros, heterocicloalquilo de 4-10 miembros-C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo, en el que dicho C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C1-3 alquilo y heterocicloalquilo de 4-10 miembros -C1-3 alquilo formando Ra2, Rb2, Rc2 y Rd2 están cada uno opcionalmente sustituidos con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente de C1-6 alquilo, halo, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(>=NRe5)NR5Rd5, NRc5C(>=NRe5)NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5(O)2Rb5 y S(O)2NRc5Rd5 ; o Rc2 y Rd2 unidos al mismo átomo de N, junto con el átomo de N al que están ambos unidos, forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros o grupo heteroarilo de 5 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de C1-6 alquilo, halo, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(>=NRe5)NRc5Rd5, NRc5C(>=NRe5)NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5 y S(O)2NRc5Rd5 ; Ra3, Rb3, Rc3 y Rd3 se seleccionan cada uno independientemente de H, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C6-10 arilo, C3-7 cicloalquilo, heteroarilo de 5-10 miembros, heterocicloalquilo de 4-10 miembros-C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C1-3 alquilo y heterocicloalquilo 4-10 miembros- C1-3 alquilo, en el que dicho C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C1-3 alquilo y heterocicloalquilo 4-10 miembros-C1-3 alquilo formando Ra3, Rb3, Rc3 y Rd3 están cada uno opcionalmente sustituidos con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente de C1-6 alquilo, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRc6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)NRc6Rd6, NRc6C(O)ORa6, C(>=NRe6)NRc6Rd6, NRc6C(>=NRe6)NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, NRc6S(O)2Rb6 y S(O)2NRc6Rd6; o Rc3 y Rd3 unidos al mismo átomo de N, junto con el átomo de N al que están ambos unidos, forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros o grupo heteroarilo de 5 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de C1-6 alquilo, halo, CN, ORa6, SRa6, C(O)Rb6, C(O)NRc6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)NRc6Rd6, NRc6C(O)ORa6, C(>=NRe6)NRc6Rd6, NRc6C(>=NRe6)NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, NRc6S(O)2Rb6 y S(O)2NRc6Rd6 ; Ra4, Rb4, Rc4 y Rd4 se seleccionan cada uno independientemente de H, C1-6 alquilo, C1-6 haloalquilo, C2-6 alquenilo, C2-6 alquinilo, arilo, C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo- C1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo, en el que dicho C1-6 alquilo, C1-6 haloalquilo, C2-6 alquenilo, C2-6 alquinilo C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C 1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo formando Ra4, Rb4, Rc4 y Rd4 están cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de OH, CN, amino, NH(C1-6 alquilo), N(C1-6 alquilo)2, halo, C1-6 alquilo, C1-6 alcoxi, C1-6 haloalquilo y C1-6 haloalcoxi; o Rc4 y Rd4 unidos al mismo átomo de N, junto con el átomo de N al que están ambos unidos, forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros o grupo heteroarilo de 5 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de OH, CN, amino, NH(C1-6 alquilo), N(C1-6 alquilo)2, halo, C1-6 alquilo, C1-6 alcoxi, C1-6 haloalquilo y C1-6 haloalcoxi; Ra5, Rb5, Rc5 y Rd5 se seleccionan 5 cada uno independientemente de H, C1-6 alquilo, C1-6 haloalquilo, C2-6 alquenilo, C2-6 alquinilo, arilo, C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo- C1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo, en el que dicho C1-6 alquilo, C1-6 haloalquilo, C2-6 alquenilo, C2-6 alquinilo C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C 1-3 alquilo y 4-10 miembros heterocicloalquilo-C1-3 alquilo formando Ra5, Rb5, Rc5 y Rd5 están cada uno opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados independientemente de OH, CN, amino, NH(C1-6 alquilo), N(C1-6 alquilo)2, halo, C1-6 alquilo, C1-6 alcoxi, C1-6 haloalquilo y C1-6 haloalcoxi; o Rc5 y Rd5 unidos al mismo átomo de N, junto con el átomo de N al que están ambos unidos, forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros o grupo heteroarilo de 5 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de OH, CN, amino, NH(C1-6 alquilo), N(C1-6 alquilo)2, halo, C1-6 alquilo, C1-6 alcoxi, C1-6 haloalquilo y C1-6 haloalcoxi; Ra6, Rb6, Rc6 y Rd6 se seleccionan cada uno independientemente de H, C1-6 alquilo, C1-6 haloalquilo, C2-6 alquenilo, C2-6 alquinilo, arilo, C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo- C1-3 alquilo y heterocicloalquilo de 4-10 miembros-C1-3 alquilo, en el que dicho C1-6 alquilo, C1-6 haloalquilo, C2-6 alquenilo, C2-6 alquinilo C6-10 arilo-C1-3 alquilo, heteroarilo de 5-10 miembros-C1-3 alquilo, C3-7 cicloalquilo-C 1-3 alquilo y 4-10 miembros heterocicloalquilo-C1-3 alquilo formando Ra6, Rb6, Rc6 y Rd6 están cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de OH, CN, amino, NH(C1-6 alquilo), N(C1-6 alquilo)2, halo, C1-6 alquilo, C1-6 alcoxi, C1-6 haloalquilo y C1-6 haloalcoxi; o Rc6 y Rd6 unidos al mismo átomo de N, junto con el átomo de N al que están ambos unidos, forman un grupo heterocicloalquilo de 4, 5, 6 ó 7 miembros o grupo heteroarilo de 5 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente de OH, CN, amino, NH(C1-6 alquilo), N(C1-6 alquilo)2, halo, C1-6 alquilo, C1-6 alcoxi, C1-6 haloalquilo y C1-6 haloalcoxi; y Re1, Re2, Re3, Re4, Re5 y Re6 son cada uno, independientemente, H, CN o NO2
ES14702167T 2013-01-14 2014-01-14 Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim Active ES2649156T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752249P 2013-01-14 2013-01-14
US201361791275P 2013-03-15 2013-03-15
PCT/US2014/011487 WO2014110574A1 (en) 2013-01-14 2014-01-14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2649156T3 true ES2649156T3 (es) 2018-01-10

Family

ID=50030545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14702167T Active ES2649156T3 (es) 2013-01-14 2014-01-14 Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim

Country Status (7)

Country Link
US (2) US9278950B2 (es)
EP (1) EP2943485B1 (es)
JP (1) JP6437452B2 (es)
CA (1) CA2897200C (es)
ES (1) ES2649156T3 (es)
HK (1) HK1216316A1 (es)
WO (1) WO2014110574A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
CN105051029B (zh) 2013-01-15 2018-07-31 因赛特公司 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en) * 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
EP3848373A1 (en) * 2016-02-19 2021-07-14 Phoenix Molecular Designs N-(1-((heterocyclyl)methyl)-1h-pyrazol-4-yl)-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
CN106336371A (zh) * 2016-08-16 2017-01-18 成都百事兴科技实业有限公司 叔丁氧羰基‑l‑焦谷氨酸甲酯的合成方法
WO2018083085A1 (en) * 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3085259A1 (en) 2017-12-13 2019-06-20 Lupin Limited Substituted bicyclic heterocyclic compounds as prmt5 inhibitors

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
WO2002055489A2 (en) 2000-12-27 2002-07-18 Univ Columbia Pim kinase-related methods
DE10123055A1 (de) 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase
DE10226702A1 (de) 2002-06-14 2004-09-09 Grünenthal GmbH Antisense Oligonukleotide gegen PIM1
AU2003272548A1 (en) 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
WO2006078228A1 (en) 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005033310A1 (de) 2003-10-01 2005-04-14 Grünenthal GmbH Pim-1-spezifische dsrna-verbindungen
WO2006006569A1 (ja) 2004-07-12 2006-01-19 Nihon Nohyaku Co., Ltd. フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法
DK1836169T5 (da) 2004-12-28 2023-10-09 Atnx Spv Llc Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
JP5052518B2 (ja) 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
WO2007044724A2 (en) 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
CA2626742A1 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US20090182003A1 (en) 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
US20090253156A1 (en) 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
CA2656564C (en) 2006-06-29 2015-06-16 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008022164A2 (en) 2006-08-16 2008-02-21 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP2078004B1 (en) 2006-10-31 2015-02-25 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
AU2007316417B2 (en) 2006-11-06 2013-08-22 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AU2008221263B2 (en) * 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
CA2682231A1 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
RU2467008C2 (ru) 2007-04-03 2012-11-20 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ
WO2008133955A1 (en) 2007-04-25 2008-11-06 Exelixis, Inc. 6-phenylpyrimidinones as pim modulators
KR20100017359A (ko) 2007-04-25 2010-02-16 엑셀리시스, 인코포레이티드 카제인 키나제 ⅱ （ｃｋ２）조절제로서의 피리미디논
WO2009014637A2 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US20100249030A1 (en) 2007-07-31 2010-09-30 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
CA2743756A1 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
US8617534B2 (en) 2007-11-16 2013-12-31 San Diego State University (Sdsu) Foundation Compositions and method for manipulating PIM-1 activity in circulatory system cells
CA2716755A1 (en) 2008-02-29 2009-09-03 Peter C. Chua Protein kinase modulators
AR070531A1 (es) 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) * 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
EP2296472A4 (en) 2008-05-12 2011-06-08 Amnestix Inc COMPOUNDS FOR RHO KINASE INHIBITION AND FOR LEARNING AND REMINDERING IMPROVEMENT
CN102137866A (zh) 2008-06-30 2011-07-27 赛林药物股份有限公司 羟吲哚化合物
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
MX2011002367A (es) 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
SI2344474T1 (sl) 2008-09-02 2015-12-31 Novartis Ag Pikolinamidni derivati kot kinazni inhibitorji
CN102197032B (zh) 2008-09-02 2014-07-23 诺华股份有限公司 杂环pim-激酶抑制剂
TWI577680B (zh) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
WO2010135401A2 (en) 2009-05-19 2010-11-25 San Diego State University Foundation Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
CN102458412A (zh) 2009-05-20 2012-05-16 赛林药物股份有限公司 作为激酶抑制剂的吡唑并嘧啶和相关杂环
WO2010135571A1 (en) 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
TW201602113A (zh) 2009-06-29 2016-01-16 英塞特公司 作為ｐｉ３ｋ抑制劑之嘧啶酮
WO2011025859A1 (en) 2009-08-26 2011-03-03 Cylene Pharmaceuticals, Inc. Condensed quinolines as protein kinase modulators
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2475659B1 (en) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
CN102625803A (zh) 2009-09-11 2012-08-01 赛林药物股份有限公司 药学上有用的杂环-取代的内酰胺
BR112012005970A2 (pt) 2009-09-16 2015-09-08 Cylene Pharmaceuticals Inc moduladores tricíclicos de proteína quinase
CN102647906A (zh) 2009-09-16 2012-08-22 赛林药物股份有限公司 三环化合物及其药学用途
TR201802464T4 (tr) 2009-10-29 2018-03-21 Genosco Ki̇naz i̇nhi̇bi̇törleri̇
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
JP2013510824A (ja) 2009-11-12 2013-03-28 セルビタ エス．エー． セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
US8304172B2 (en) 2009-11-12 2012-11-06 Advanced Micro Devices, Inc. Semiconductor device fabrication using a multiple exposure and block mask approach to reduce design rule violations
JP5740409B2 (ja) 2009-11-13 2015-06-24 ジェノスコ キナーゼ阻害剤
US8853235B2 (en) 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2011075613A1 (en) 2009-12-18 2011-06-23 Sanofi Azaindole derivatives, their preparation and their therapeutic application
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
KR101858097B1 (ko) 2009-12-23 2018-05-15 자스코 파머수티컬스, 엘엘씨 아미노피리미딘 키나제 억제제
GB201002861D0 (en) 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions
TWI531572B (zh) 2010-03-10 2016-05-01 英塞特公司 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物
PE20130405A1 (es) 2010-04-07 2013-04-10 Hoffmann La Roche Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CN103080106A (zh) 2010-07-06 2013-05-01 诺瓦提斯公司 用作激酶抑制剂的环醚化合物
RU2604062C2 (ru) 2010-07-13 2016-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
CN103201267B (zh) 2010-07-29 2016-08-17 里格尔药品股份有限公司 Ampk-激活性杂环化合物以及其使用方法
US8227773B2 (en) 2010-07-29 2012-07-24 Axcelis Technologies, Inc. Versatile beam glitch detection system
WO2012064981A2 (en) 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
US9090593B2 (en) 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
JP5980225B2 (ja) 2010-12-17 2016-08-31 ナーヴィアノ メディカル サイエンシズ エス．アール．エル． キナーゼ阻害剤としての置換ピラゾロ−キナゾリン誘導体
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
BR112013018515B1 (pt) 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
EP2668188B1 (en) 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
RU2598846C2 (ru) 2011-02-25 2016-09-27 Эррэй Биофарма Инк. Триазолопиридиновые соединения как ингибиторы киназы pim
EP2681197A1 (en) * 2011-03-04 2014-01-08 Novartis AG Tetrasubstituted cyclohexyl compounds as kinase inhibitors
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
AU2012230890A1 (en) 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2832291C (en) 2011-04-05 2015-12-01 Pfizer Limited Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
EP2702055A1 (en) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
US8901145B2 (en) 2011-04-22 2014-12-02 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
US20140288069A1 (en) 2011-05-17 2014-09-25 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012156756A2 (en) 2011-05-19 2012-11-22 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
JP2014522396A (ja) 2011-05-27 2014-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 置換２−ベンジリデン−２Ｈ−ベンゾ［ｂ］［１，４］チアジン−３（４Ｈ）−オン、その誘導体及びその治療上の使用
CN103717604B (zh) 2011-06-01 2016-06-01 拜耳知识产权有限责任公司 取代的氨基咪唑并哒嗪
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
ES2610366T3 (es) 2011-06-22 2017-04-27 Bayer Intellectual Property Gmbh Heterociclil-aminoimidazopiridazinas
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
CN102924445B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
MX355852B (es) 2011-08-12 2018-05-02 Hoffmann La Roche Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
JP5843524B2 (ja) 2011-09-02 2016-01-13 キヤノン株式会社 有機無機複合組成物、有機無機複合材料、光学素子および積層型回折光学素子
TWI648277B (zh) 2011-09-02 2019-01-21 美商英塞特控股公司 作為ｐｉ３ｋ抑制劑之雜環基胺
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9320737B2 (en) 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2788351B1 (en) 2011-10-07 2017-06-28 Nerviano Medical Sciences S.r.l. SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASE INHIBITORS
US9181258B2 (en) 2011-10-07 2015-11-10 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
BR112014010563B1 (pt) 2011-11-04 2021-01-12 Jasco Pharmaceuticals, LLC compostos inibidores da aminopirimidina quinase
WO2013130660A1 (en) 2012-02-28 2013-09-06 Amgen Inc. Amides as pim inhibitors
WO2013134079A1 (en) 2012-03-05 2013-09-12 Amgen Inc. Oxazolidinone compounds and derivatives thereof
JP6173426B2 (ja) 2012-03-29 2017-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ アミノ置換イミダゾピリダジン
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9409889B2 (en) 2012-04-04 2016-08-09 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
KR102098804B1 (ko) 2012-04-26 2020-04-08 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체
EA025050B1 (ru) 2012-04-27 2016-11-30 Новартис Аг Циклические мостиковые простые эфиры в качестве ингибиторов dgat1
EA036639B1 (ru) 2012-05-09 2020-12-02 Байоджен Ма Инк. Модуляторы ядерного транспорта и их применение
PT2861579T (pt) 2012-05-15 2018-04-27 Novartis Ag Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2013264831B2 (en) 2012-05-21 2016-04-21 Novartis Ag Novel ring-substituted N-pyridinyl amides as kinase inhibitors
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP6242885B2 (ja) 2012-06-27 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ５−アザインダゾール化合物及び使用方法
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
CN103664878A (zh) 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
PE20150777A1 (es) 2012-09-14 2015-06-20 AbbVie Deutschland GmbH and Co KG Derivados triciclicos de quinolinas y de quinoxalinas
CN104640858B (zh) 2012-09-26 2018-11-06 霍夫曼-拉罗奇有限公司 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
WO2014053568A1 (en) 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
PE20150723A1 (es) 2012-10-16 2015-05-15 Janssen Sciences Ireland Uc Compuestos antiviricos para el vsr
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
DK2941432T3 (en) 2012-12-07 2018-06-14 Vertex Pharma 2-amino-6-fluoro-N- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3-yl) pyrazolo [ 1,5ALPHA] PYRIMIDIN-3-CARBOXAMIDE AS ATR-KINASE INHIBITOR
WO2014088117A1 (ja) 2012-12-07 2014-06-12 トヨタ自動車株式会社 車体端部構造
BR112015014458B1 (pt) 2012-12-18 2022-06-21 Vertex Pharmaceuticals Incorporated Compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112015014372A8 (pt) 2012-12-19 2019-10-29 Novartis Ag inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
LT2935222T (lt) 2012-12-21 2018-12-27 Epizyme, Inc. Prmt5 slopikliai ir jų panaudojimas
JP6028105B2 (ja) 2012-12-21 2016-11-16 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびその薬学的用途
FR3000569B1 (fr) 2013-01-03 2015-02-13 Peugeot Citroen Automobiles Sa Dispositif d'eclairage a ecran a bord(s) lumineux
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
CN105051029B (zh) 2013-01-15 2018-07-31 因赛特公司 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
TWI689489B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014139145A1 (en) 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
UY35421A (es) 2013-03-15 2014-10-31 Nihon Nohyaku Co Ltd Compuesto heterocíclico condensado o su sal, insecticida agrícola u hortícola que comprende el comp uesto y método de uso del insecticida
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102305436B1 (ko) 2013-03-15 2021-09-27 코르테바 애그리사이언스 엘엘씨 4-아미노-6-(헤테로시클릭)피콜리네이트 및 6-아미노-2-(헤테로시클릭)피리미딘-4-카르복실레이트 및 제초제로서의 그의 용도
AU2014230569B2 (en) 2013-03-15 2017-11-23 Japan Tobacco Inc. Pyrazole-amide compound and medicinal uses therefor
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
LT2970236T (lt) 2013-03-15 2017-11-10 Idorsia Pharmaceuticals Ltd Piridin-4-ilo dariniai
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
BR112015022942B1 (pt) 2013-03-15 2022-02-22 Incyte Holdings Corporation Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CR20160449A (es) 2014-02-28 2016-12-20 Incyte Corp Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos
SG10201808870TA (en) 2014-04-08 2018-11-29 Incyte Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
KR20170007331A (ko) 2014-04-30 2017-01-18 인사이트 코포레이션 Jak1 억제제의 제조 방법 및 이에 대한 신규한 형태
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors

Also Published As

Publication number Publication date
CA2897200C (en) 2021-07-06
CA2897200A1 (en) 2014-07-17
US20160137626A1 (en) 2016-05-19
US9676750B2 (en) 2017-06-13
JP6437452B2 (ja) 2018-12-12
WO2014110574A1 (en) 2014-07-17
EP2943485B1 (en) 2017-09-20
JP2016505021A (ja) 2016-02-18
HK1216316A1 (zh) 2016-11-11
EP2943485A1 (en) 2015-11-18
US20140200216A1 (en) 2014-07-17
US9278950B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
ES2649156T3 (es) Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR084425A1 (es) Derivados heterociclicos de 8-azabiciclo[3.2.1]octan-8-ilo, composiciones farmaceuticas que los contienen, proceso para prepararlos e intermediarios y uso de los mismos para tratar patologias hepaticas tales como dislipemias e hipercolesterolemia entre otras
AR079529A1 (es) Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
ES2616477T3 (es) Heterociclaminas como inhibidores de pi3k
EA201490859A1 (ru) Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
ES2618003T3 (es) Compuestos tricíclicos sustituidos como inhibidores de FGFR
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
AR093562A1 (es) Composiciones y compuestos antihelminticos y metodo para usarlos
PE20190446A1 (es) Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20161443A1 (es) Compuestos
EA201591078A1 (ru) Пептиды в качестве агонистов окситоцина
AR085316A1 (es) Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
PE20160839A1 (es) Derivados de 4-azaindol
PE20150943A1 (es) 2-oxo-2,3-dihidro-indoles para el tratamiento de desordenes de cns
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
AR111682A1 (es) Derivados de imidazopirimidina con sustituyentes fenilo y piridilo que contienen azufre